Andrew Davis is Vice President at Scheer Partners and helps run the scientific real estate practice. Andrew lives in Maryland but assists scientific companies identify, negotiate, and build space in the Biohealth Capital Region, Philadelphia / Greater PA, and Massachusetts.
Graybug Vision files for $86 Million IPO on NASDAQ (GRAY)
Griffin St Louis Joins TEDCO as Program Manager, Maryland Innovation Initiative (MII)
Perhaps the single biggest challenge faced by startup entrepreneurs and early-stage life science companies is securing the necessary funding to fuel innovation and growth. The BioHealth Capital Region (BHCR) life science community as a whole faces a similar challenge when it comes to access to venture capital funding; this challenge has been noted by many BHCR thought leaders and well-documented in a host of BioBuzz stories.
BioHealth Innovation (BHI) was created in 2012 by Rich Bendis and key industry leaders to accelerate the commercialization of high potential scientist entrepreneurs and companies within the BioHealth Capital Region (BHCR), which consists of Maryland, Virginia and Washington, D.C.
Raising Capital During a Pandemic: Strong Networks and Respected Advocates Remain Critical to Fundraising Efforts
Raising Capital During a Pandemic: Strong Networks and Respected Advocates Remain Critical to Fundraising Efforts Talk to any experienced venture capital investor and they’ll tell you that personal, face-to-face interactions [….]
$1.2M Seed Round puts Maryland’s Pathotrak on Course to Disrupt $10B Food Safety Market with Rapid Testing Technology
$1.2M Seed Round puts Maryland’s Pathotrak on Course to Disrupt $10B Food Safety Market with Rapid Testing Technology June 9, 2020 Pathotrak, a startup focused on developing novel food safety [….]
2020 Life Science Venture Capital Funding Roundup for Q1/Q2 in the BioHealth Capital Region BioHealth Companies raised more than $178M in the first half of 2020 June 9, 2020 This [….]
Baltimore, Maryland’s LifeSprout Closes $28.5M Series-A, Looks Toward the Future LifeSprout, a privately-held regenerative medicine company located in Baltimore, Maryland, recently announced the closing of a $28.5M Series A financing [….]